Printer Friendly

ORTEC SUCCESSFULY DEFENDS EUROPEAN PATENT ON ORCEL.

Ortec International (Nasdaq:ORTC), New York, has successfully defended an opposition filed with the European Patent Office by Advanced Tissue Sciences, Inc. challenging the validity of Ortec's European patent on OrCel(TM), Ortec's tissue engineering platform technology.

Commenting on the successful defense, Steven Katz, Ph.D., Ortec's chairman and CEO stated, "This is the second challenge from a competitor Ortec has successfully defended. We have always felt confident in the strength of our patent, and the European Patent Office's decision reaffirms the novelty and inventiveness of Ortec's leading technology." Advanced Tissue Sciences has the right to appeal for two months following the official date of issuance of the decision.

Ortec was originally granted the European patent on its OrCel technology on December 29,1997 (patent #EP0526550) and received notification that it was being challenged by Advanced Tissue Sciences November 5, 1998. In 1996, Ortec successfully defended its U.S. patent on OrCel in a patent reexamination challenge by Organogenesis, another competitor of Ortec. In addition, Ortec has also recently filed several patents in the U.S. for processes relating to its cryopreservation, cell production and manufacturing.

About Ortec International, Inc.

Ortec International, Inc., (Nasdaq:ORTC), is a tissue-engineering company involved in the commercialization of a proprietary and patented technology to stimulate the repair and regeneration of human tissue. Ortec's current focus is the application of its OrCel(TM) (Bilayered Cellular Matrix) to heal chronic and acute wounds. OrCel is composed of a collagen sponge seeded with allogeneic epidermal and dermal cells. These cells secrete growth factors and cytokines normally found in acute human wounds and are believed to have a beneficial role in promoting tissue repair. In addition to having received FDA approvals during 2001 for the treatment of Epidermolysis Bullosa and donor sites in burn patients, Ortec is also pursuing FDA approvals for venous and diabetic skin ulcers and is in the midst of clinical trials for these indications. Ortec believes that its platform technology may extend to the regeneration of other human tissue such as tendons, ligaments, cartilage, bone, muscle and blood vessels.

For more information, visit http://www.ortecinternational.com or call 212/740-6999, ext. 204
COPYRIGHT 2002 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Comment:ORTEC SUCCESSFULY DEFENDS EUROPEAN PATENT ON ORCEL.
Publication:Worldwide Biotech
Geographic Code:1USA
Date:May 1, 2002
Words:359
Previous Article:ALLIANCE PLANS EUROPEAN PHASE 3 STUDY FOR OXYGENT.
Next Article:FDA CLEARS THROMBOLYTIC DRUG FOR PHASE II CLINICAL TRIAL.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters